A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
Clinical trial NCT04365933 · COMPLETED
Trial details
- NCT number
- NCT04365933
- Sponsor
- Enyo Pharma
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-25
- Primary completion
- 2021-06-16
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.